The regulation, which is subject to Parliament approval, will require the MHRA to authorise all drug trials. Furthermore, the legislation requires the studies to be conducted in line with Good Clinical Practice.

In addition, the government outlined requirements for the evaluation and supply of investigational medicinal products as well as safety reporting.

The legislation also includes multiple amendments to the Clinical Trials Regulations, including instructions for interpretation, sponsor of a trial and authorisation procedure.

The government also published two separate contingency legislations for medicines and medical devices, respectively, in case the UK had to leave the European Union (EU) without an official deal.

This announcement comes soon after a report that universities in the UK have failed to post data from nearly 1,671 clinical trials onto registries, violating reporting rules.

In this regard, UK Science and Technology Select Committee chair Norman Lamb has written to more than 40 universities on their practices to meet clinical trials transparency requirements.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The universities have been asked to ensure that measures are taken to comply with existing transparency rules and legislation in the future.

Lamb said: “The Committee applauds the universities that have reacted quickly to the clinical trials transparency problems we identified in October.

“However, it’s deeply disappointing that on the face of it most have failed to respond to the challenge so far. Universities and other trial leaders need to act on this as a matter of urgency.”

The Committee intends to carry out a follow-up evidence session regarding the trial transparency issue.